

Yoshiaki Uyama

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2600836/publications.pdf>

Version: 2024-02-01

10
papers

109
citations

1937457

4
h-index

1474057

9
g-index

10
all docs

10
docs citations

10
times ranked

63
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 523-529.	0.8	5
2	Validity of identification algorithms combining diagnostic codes with other measures for acute ischemic stroke in <sc>MID-NET [®] </sc>. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 524-533.	0.9	6
3	Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET [®] Medical Information Database Network in Japan. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 625-631.	0.8	4
4	Effect of Hepatitis C Drugs on Blood Coagulability in Patients on Warfarin Using the Medical Information Database Network (MID-NET [®]) in Japan. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 539-544.	0.8	5
5	Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive Analysis. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1075-1081.	0.8	1
6	Characteristics on Drug Safety Measures in Japan Stratified by System Organ Classes and Therapeutic Categories in Relation to the Approval Date. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1534-1540.	0.8	0
7	Identification of gastrointestinal perforation based on ICD-10 code in a Japanese administrative medical information database and associated drug exposure risk factors. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 976-984.	0.9	5
8	Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1166-1174.	0.9	8
9	Establishment of the MID-NET [®] medical information database network as a reliable and valuable database for drug safety assessments in Japan. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1395-1404.	0.9	49
10	The utilization and challenges of Japan's MID-NET [®] medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 601-608.	0.9	26